Back to Search
Start Over
Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up.
- Source :
-
Annals of Oncology . Sep2012, Vol. 23 Issue 9, p2380-2385. 6p. 1 Diagram, 1 Chart, 4 Graphs. - Publication Year :
- 2012
-
Abstract
- Background The purpose of this study was to report long-term results of rituximab induction monotherapy in patients with low-tumor-burden follicular lymphoma (LTBFL). Patients and methods Of 49 first-line LTBFL patients who received weekly doses of rituximab (375 mg/m2), 46 have been followed with a long-term analysis of clinical and molecular responses. Results Best clinical response (at any staging within a year following treatment) was 80%, 24 (52%) patients had complete or unconfirmed complete response, 13 (28%) had partial response and 9 (20%) had stable or progressive disease. Of 31 patients having a positive bcl2-JH rearrangement, 15 (48%) became negative following treatment. Conclusion A significant proportion of patients remain progression-free 7 years after a single 4-dose rituximab treatment in first-line LTBFL. The 7-year overall survivalOS is very high in this selected population of patients. [ABSTRACT FROM PUBLISHER]
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 23
- Issue :
- 9
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 79444916
- Full Text :
- https://doi.org/10.1093/annonc/mds177